Back to Search Start Over

Impact of the COVID-19 pandemic on paediatric patients with cancer in low-income, middle-income and high-income countries: protocol for a multicentre, international, observational cohort study

Authors :
Mohamed Ahmed
Vaishnavi Govind
Darica Au
Kokila Lakhoo
Noel Peter
Maryam Khan
Marta de Andres Crespo
Alexandra Valetopoulou
Soham Bandyopadhyay
Elliott H Taylor
Somy Charuvila
Anna Casey
Muhammed Elhadi
Shaun Wilson
Poorvaprabha Patil
Mahan Salehi
Simone Abib
Hafeez Abdelhafeez
Max Pachl
Benjamin Martin
Sonal Nagras
Mihir Sheth
Catherine Dominic
Suraj Gandhi
Divya Parwani
Rhea Raj
Diella Munezero
Rohini Dutta
Nsimire Mulanga Roseline
Kellie McClafferty
Armin Nazari
Smrithi Sriram
Sai Pillarisetti
King-David Nweze
Aishwarya Ashwinee
Gul Kalra
Priyansh Nathani
Khushman Kaur Bhullar
Nehal Rahim
Shweta Madhusudanan
Joshua Erhabor
Manasi Shirke
Aishah Mughal
Sravani Royyuru
Syeda Namayah Fatima Hussain
Daniel Robinson
Mehdi Khan
Alexandre Dukundane
Kwizera Festus
Rohan Pancharatnam
Lorraine Ochieng
Hritik Nautiyal
Source :
BMJ Open, Vol 11, Iss 6 (2021)
Publication Year :
2021
Publisher :
BMJ Publishing Group, 2021.

Abstract

Introduction Childhood cancers are a leading cause of non-communicable disease deaths for children around the world. The COVID-19 pandemic may have impacted on global children’s cancer services, which can have consequences for childhood cancer outcomes. The Global Health Research Group on Children’s Non-Communicable Diseases is currently undertaking the first international cohort study to determine the variation in paediatric cancer management during the COVID-19 pandemic, and the short-term to medium-term impacts on childhood cancer outcomes.Methods and analysis This is a multicentre, international cohort study that will use routinely collected hospital data in a deidentified and anonymised form. Patients will be recruited consecutively into the study, with a 12-month follow-up period. Patients will be included if they are below the age of 18 years and undergoing anticancer treatment for the following cancers: acute lymphoblastic leukaemia, Burkitt lymphoma, Hodgkin lymphoma, Wilms tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas and neuroblastomas. Patients must be newly presented or must be undergoing active anticancer treatment from 12 March 2020 to 12 December 2020. The primary objective of the study was to determine all-cause mortality rates of 30 days, 90 days and 12 months. This study will examine the factors that influenced these outcomes. χ2 analysis will be used to compare mortality between low-income and middle-income countries and high-income countries. Multilevel, multivariable logistic regression analysis will be undertaken to identify patient-level and hospital-level factors affecting outcomes with adjustment for confounding factors.Ethics and dissemination At the host centre, this study was deemed to be exempt from ethical committee approval due to the use of anonymised registry data. At other centres, participating collaborators have gained local approvals in accordance with their institutional ethical regulations. Collaborators will be encouraged to present the results locally, nationally and internationally. The results will be submitted for publication in a peer-reviewed journal.

Subjects

Subjects :
Medicine

Details

Language :
English
ISSN :
20446055
Volume :
11
Issue :
6
Database :
Directory of Open Access Journals
Journal :
BMJ Open
Publication Type :
Academic Journal
Accession number :
edsdoj.9e94fb08809141a38fca2b29a01ef2b8
Document Type :
article
Full Text :
https://doi.org/10.1136/bmjopen-2020-045679